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Abstract
Patients with liver-dominant metastatic colorectal cancer (mCRC) beneﬁt from increased control of the hepatic
disease. Radioembolization (RE) can provide signiﬁcant hepatic tumor control in eligible patients, but
advanced age is a factor of unclear importance. Fortunately, results from an 11-center experience demonstrate
similar safety and efﬁcacy with RE in patients < 70 years of age and patients ‡ 70 years of age.
Background: The effects of advancing age on clinical outcomes after radioembolization (RE) in patients with unre-
sectable liver-dominant metastatic colorectal cancer (mCRC) are largely unknown. Patients and Methods: This study
was a retrospective analysis of 160 elderly ( 70 years) and 446 younger (< 70 years) consecutive patients from 11 US
centers who received RE using ytrrium-90 (90Y) resin microspheres (90Y radioembolization [90Y-RE]) between July 2002
and December 2011. A further analysis was conducted in 98 very elderly patients ( 75 years). Statistical analyses of
safety, tolerability, and overall survival were conducted. Results: Mean ages ( standard deviation) in the younger
(< 70 years), elderly ( 70 years), and very elderly ( 75 years) cohorts were 55.9  9.4 years, 77.2  4.8 years, and
80.2  3.8 years, respectively. Overall survival was similar between elderly and younger patients: 9.3 months (95%
conﬁdence interval [CI], 8.0-12.1) and 9.7 months (95% CI, 9.0-11.4) (P ¼ .335). There were no differences between
cohorts for any grade adverse events (P ¼ .433) or grade 3þ events (P ¼ .482). Analysis of patients  75 years
and < 75 years conﬁrmed similar overall survival (median, 9.3 months vs. 9.6 months, respectively; P ¼ .987) and
grade 3þ events (P ¼ .398) or any adverse event (P ¼ .158) within 90 days of RE. Conclusion: For patients with
unresectable liver-dominant mCRC who meet eligibility criteria for RE, 90Y-RE microspheres appear to be effective and
well-tolerated, regardless of age. Criteria for selecting patients for RE should not include age for exclusion from this
potentially beneﬁcial intervention.
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Safety and Efﬁcacy of Radioembolization in mCRCIntroduction
Colorectal cancer (CRC) is the fourth most commonly diagnosed
cancer in the United States.1 Median age at diagnosis is 69 years,
with 60% of new cases each year affecting patients older than 65
years (including 36% who are  75 years).1 Studies of palliative and
curative therapies purport similar outcomes in the elderly and young
alike, demonstrating that chronologic age by itself is not a contra-
indication to treatment.2 Nevertheless, population-based registries
in the United States and Europe show that elderly patients ( 75
years) with CRC were 70% to 90% less likely to receive chemo-
therapy or radiotherapy than were younger patients,3 despite evi-
dence that many could have beneﬁted from these treatments4-9 and
were less likely to receive surgical resection of the primary and/or
secondary tumor.9-13 With an underrepresentation of elderly pa-
tients in clinical trials,14 only a few population-based studies have
evaluated the true impact of treatment on the elderly.9,15 To date,
there is little guidance on the best treatment strategy for elderly
patients with CRC taking into consideration both age-related16,17
and treatment-related factors18-20 to improve outcomes. Only 1
report to date has speciﬁcally studied age in patients receiving
radioembolization (RE) for hepatic metastases from CRC.21 In this
retrospective study of 107 patients with CRC liver metastases
treated at a single institution, 44 patients aged 70 years or older at
the time of RE were compared with 63 patients younger than 70
years of age. Their conclusion was that toxicities and median sur-
vival were similar in both age groups after RE.21
The aim of this analysis from the Metastatic Colorectal Cancer
Liver Metastases Outcomes After RadioEmbolization (MORE)
study was to evaluate the effects of advancing age on the clinical
outcomes after RE with yttrium-90 (90Y)-labeled resin microspheres
(90Y radioembolization [90Y-RE]). Data from the primary analyses
in the overall cohort are published elsewhere.22
Patients and Methods
A retrospective study was conducted of consecutive patients who
were referred to 11 US tertiary care centers for RE using 90Y resin
microspheres (SIR-Spheres; Sirtex, Sydney, Australia) between July
2002 and December 2011 (clinicaltrials.gov identiﬁer:
NCT01815879). All patients with a diagnosis of metastatic CRC
(mCRC) who received at least 1 RE treatment and had at least 1
follow-up visit were included in the analyses. Institutional review
board exemptions were granted before the collection of data at each
site.
Centers were guided in the selection of patients, pretreatment
workup, and dosimetry by the published consensus from the
Radioembolization Brachytherapy Oncology Consortium
(REBOC) and other earlier reviews.23-25 90Y-RE was considered for
those patients with advanced liver-dominant mCRC who were not
suitable for (or who refused consent, or both) surgery, ablation, or
systemic therapy or whose disease had progressed or who had
become intolerant to at least 1 line of systemic therapy. Good
candidates for 90Y-RE included those with liver-only or liver-
dominant mCRC, Eastern Cooperative Oncology Group
(ECOG) performance status score of  2, and untreated life ex-
pectancy of  12 weeks. Patients with limited hepatic reserve, as-
cites, or other clinical signs of liver failure (total bilirubin level > 2.0
mg/dL in the absence of a reversible cause; serum albumin levelClinical Colorectal Cancer June 2016of < 3.0 g/dL), or compromised bone marrow or pulmonary
function were generally considered unsuitable for 90Y-RE. During
the pretreatment workup, patients were excluded from RE if there
was evidence of any uncorrectable ﬂow to nontarget sites (eg,
gastrointestinal tract or other extrahepatic organs) observed on
angiography or a technetium-99m macroaggregated albumin
(99mTc-MAA) scan. Under exceptional circumstances and with
informed consent, some patients were treated outside the criteria
outlined based on the clinical judgment of the treating physicians.
The protocol for treatment within a single session or over mul-
tiple sessions (eg, using a sequential lobar approach for bilobar liver
metastases) is reported elsewhere.24 Most activity calculations for
90Y-RE were planned using the body surface area methodology
according to consensus guidelines.
Data Collection and Analysis
Safety data were collated on the day of the ﬁrst 90Y-RE procedure
(day 0) and at all subsequent visits and included the results from all
hematologic, liver function, and blood biochemistry tests and
physical examinations. The nature and severity of all adverse events
were graded using the Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0.26 The highest grade occurring at any
time between day 0 and day 90 after the procedure were reported.
Survival was calculated from the day of the ﬁrst 90Y-RE procedure
to the day of death or last follow-up.
Statistical Analysis
Statistical analyses were conducted using SAS, XP Pro, version
9.2, statistical analysis software (SAS Institute, Cary NC).
Nonparametric estimates of survival were computed using the
Kaplan-Meier product-limit method. The P values for continuous
baseline variables were assessed by 1-way analysis of variance, for
dichotomous variables by the Fisher exact test, and for nominal
categorical variables by the c2 general association test. The CTCAE
distribution between cohorts was compared using the Cochran-
Mantel-Haenszel test.
Results
Patients
The baseline characteristics of 160 elderly ( 70 years) and 446
younger (< 70 years) patients are presented in Table 1, and the
baseline characteristics of 98 very elderly patients ( 75 years) are
presented in Supplemental Table 1 (see the online version). Mean
ages ( standard deviation) in the younger (< 70 years), elderly (
70 years), and very elderly ( 75 years) cohorts were 55.9  9.4
years, 77.2  4.8 years, and 80.2  3.8 years, respectively.
Regardless of age, patients eligible for 90Y-RE had statistically
similar baseline characteristics, although compared with the younger
(< 70 years) patients, elderly ( 70 years) patients were more likely
to have metachronous liver metastases (P < .001), to have had
previous resection for a primary tumor (P ¼ .009), to have received
fewer lines of treatment (P ¼ .036) or no previous chemotherapy
(P < .001), and to have had a longer period between diagnosis and
90Y-RE (P ¼ .011). Notably, elderly patients were signiﬁcantly less
likely to have received previous treatment with oxaliplatin, irinote-
can, and bevacizumab. Similar trends were also observed in the very
elderly cohort ( 75 years) (see Supplemental Table 1 in the online
Table 1 Baseline Patient and Disease Characteristics, and Previous Procedures (N [ 606)
Parameter Category
Elderly Patients (‡70
years; n [ 160) N (%)a
Younger Patients (<70
years; n [ 446) N (%)a
P Value
Across
Cohorts
Sex, N (%) Female/male 59 (36.9)/101 (63.1) 174 (39.0)/272 (61.0) .705
Age, years Mean  SD (range) 77.2  (70.1-91.9) 55.9  (20.8-69.9) <.001
75 years 98 (61.3%) NA
Race, N (%)b White or Caucasian 101 (63.1) 297 (66.6) .429c
Black or African American 11 (6.9%) 56 (12.6)
Hispanic or Latino 3 (1.9) 14 (3.1)
Asian 4 (2.5) 8 (1.8)
Other 5 (3.1) 13 (2.9)
Unknown 36 58
ECOG Performance
Status, N (%)d
0 41 (57.7) 127 (68.3) .112e
1 24 (33.8) 48 (25.8)
2 5 (7.0) 9 (4.8)
3 1 (1.4) 2 (1.1)
Unknown 89 260
Site of Primary
Tumor, N (%)f
Colon 135 (84.9) 308 (69.2) .055g
Rectum 21 (13.2) 112 (25.2)
Colorectal 3 (1.9) 25 (5.6)
Primary Tumor
in Situ N (%)h
11 (7.1) 67 (15.1) .009
Metastases (%)i,j Metachronous 64 (43.0) 109 (26.0) <.001
Synchronous 85 (57.0) 311 (74.0)
Extrahepatic
Metastases, N (%)
55 (34.4) 158 (35.4) .847
Ascites, N (%) k Yes 6 (3.9) 22 (5.0) .555
Previous Liver-Directed
Procedures, N (%)
Surgery or ablation, or both 47 (29.4) 121 (27.1) .607
Vascular/percutaneous 7 (4.4) 30 (6.7) .340
Upper abdominal radiation therapy 3 (1.9) 4 (0.9) .388
Previous lines Of
Systemic Chemotherapy
for mCRC, N (%)
90Y-RE ﬁrst line 21 (13.6) 14 (3.3) <.001
90Y-RE second line 50 (32.5) 156 (36.4) .058l
90Y-RE third line 46 (29.9) 138 (32.2)
90Y-RE fourth line plus 37 (24.0) 121 (28.2)
Unknown 6 17
Previous Chemotherapeutic
Agents, N (%)
Fluoropyrimidine 133 (83.1) 402 (90.1) .022
Oxaliplatin 107 (66.9) 350 (78.5) .005
Irinotecan 63 (39.4) 233 (52.2) .006
Bevacizumab 90 (56.3) 319 (71.5) <.001
EGFR inhibitor 42 (26.3) 124 (27.8) .757
Time from mCRC Diagnosis
to 90Y-RE, monthsm
Median (range) 19.2 (0.4-90.6) 15.7 (0.6-96.3) .295
Tumor-to-Treated Liver
Volume (ﬁrst session), N (%)n
<25 95 (66.4) 293 (70.6) .709
25-50 42 (29.4) 106 (25.5)
>50 6 (4.2) 16 (3.9)
Albumin, g/dLo Median (IQR) 3.6 (0.8) 3.7 (0.7) .112
CTCAE grade 1, N (%) 61 (38.9) 138 (31.8) .116
Total Bilirubin, mg/dLp Median (IQR) 0.7 (0.4) 0.6 (0.4) .863
CTCAE grade 1, N (%) 7 (4.5) 30 (6.9) .339
Alkaline Phosphatase, U/Lk Median (IQR) 149.5 (148.5) 144.5 (138.0) .787
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Table 1 Continued
Parameter Category
Elderly Patients (‡70
years; n [ 160) N (%)a
Younger Patients (<70
years; n [ 446) N (%)a
P Value
Across
Cohorts
CTCAE grade 1, N (%) 95 (60.9) 256 (58.7) .704
Creatinine, mg/dLq Median (IQR) 1.0 (0.4) 0.8 (0.3) <.001
CTCAE grade 1, N (%) 16 (10.1) 10 (2.3) <.001
Hemoglobin, g/dLr Median (IQR) 12.2 (2.5) 12.5 (2.5) .150
CTCAE grade 1, N (%) 73 (46.2) 165 (37.8) .072
Neutrophils, 3109/Ls Median (IQR) 6.9 (2.9) 6.4 (3.2) .184
CTCAE grade 1, N (%) 4 (2.5) 37 (8.5) .010
Unknown 133 346
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; EGFR ¼ endothelial growth factor receptor; IQR ¼ interquartile range; mCRC ¼ metastatic colorectal carcinoma; SD ¼ standard
deviation.
aCalculated as a proportion of patients with known baseline data.
bMissing patient baseline data on 94 patients.
cP value: comparison of white (Caucasian) versus other.
dMissing patient baseline data on 349 patients.
eP value: comparison of ECOG performance status 0-1 versus 2þ.
fMissing patient baseline data on 2 patients.
gP value: comparison of colon versus rectum.
hMissing patient baseline data on 6 patients.
iMissing patient baseline data on 37 patients.
jSynchronous deﬁned as the identiﬁcation of metastases within 4 months (120 days) of the diagnosis of the primary tumor.
kMissing patient baseline data on 14 patients.
lP value: continuous variable across all lines of chemotherapy.
mMissing patient baseline data on 29 patients.
nMissing patient baseline data on 48 patients.
oMissing patient baseline data on 15 patients.
pMissing patient baseline data on 13 patients.
qMissing patient baseline data on 11 patients.
rMissing patient baseline data on 12 patients.
sMissing patient baseline data on 479 patients.
Safety and Efﬁcacy of Radioembolization in mCRC
144 -version). A greater proportion of elderly patients was also affected by
changes in kidney function at baseline (deﬁned as CTCAE grade
1þ creatinine toxicity), although fewer had grade 1þ neutropenia
(2.5% vs. 8.5%; P < .001). All patients eligible for 90Y-RE,
regardless of age, had similar liver function test ﬁndings at baseline.
Treatment
The treatment characteristics for 90Y-RE by age are presented in
Table 2 for patients  70 years versus those < 70 years and in
Supplemental Table 2 (see the online version) for patients  75
years versus those < 75 years. Overall, 97% to 98% of patients were
discharged from the hospital within 24 hours of the procedure in all
age groups. Age was not a factor in determining the treatment
approach for 90Y-RE, but elderly patients were less likely to receive
more than 1 90Y-RE procedure (P ¼ .007), and a lower volume of
liver was treated (P < .001) (Table 2). The radioactivity delivered
during the ﬁrst 90Y-RE procedure was also slightly lower in the
elderly ( 70 years) patients compared with the younger patients:
1.09 GBq (range, 0.110-2.04) versus 1.19 GBq (range, 0.130-2.29)
(P ¼ .011), although the median tumor-toetreated liver involve-
ment was not statistically different between the cohorts.
Safety and Tolerability
Table 3 reports the ﬁndings from the safety analyses within the
90 days after the ﬁrst 90Y-RE procedure in elderly ( 70 years)
patients, and these ﬁndings for very elderly ( 75 years) patients are
reported in Supplemental Table 3 (see the online version). RE
appeared to be equally well tolerated in the elderly ( 70 years) andClinical Colorectal Cancer June 2016younger patients, with no statistically signiﬁcant differences in
reporting of events by age for any grade (P ¼ .433) or grade 3þ
events (P ¼ .615), although gastrointestinal events (any grade) were
less likely to be reported in the elderly patients than in the younger
patients (Table 3). Common ( 1%) grade 3þ events reported in
the elderly ( 70 years) and the younger patients were abdominal
pain (3.1% vs. 6.1%), gastritis or duodenitis (1.3% vs. 0.2%),
nausea (0.6% vs. 1.3%), vomiting (1.3% vs. 1.3%), fatigue (5.6%
vs. 4.5%), ascites (1.3% vs. 2.0%), hyperbilirubinemia (3.8% vs.
2.7%), and RE-induced liver disease (REILD) (1.3% vs. 0.2%),
respectively. Similar ﬁndings for grade 3þ events were also observed
in the analyses of the very elderly ( 75 years), with the exception of
grade 3þ abdominal pain, which was less likely to be reported in the
very elderly (1.0% vs. 6.1%; P ¼ .029).
The most common event overall was mild to moderate fatigue,
which tended to be more frequent in the elderly patients ( 70 years)
than in the younger patients (41.3% vs. 34.5%), but between-group
differences were not statistically signiﬁcant for the reporting of this
event for all grades (P ¼ .135) or severe events (P ¼ .838). Overall,
the reporting of liver-functionerelated adverse events was low and
not statistically signiﬁcantly different compared with the younger
cohorts in the analyses of either the elderly or the very elderly.
All-cause cumulative mortality did not differ signiﬁcantly be-
tween younger patients (< 70 years) and elderly patients ( 70
years) on day 30 (3 [1.9%] vs. 9 [2.0%]; P ¼ 1.00), day 60 (10
[6.3%] vs. 27 [6.1%]; P ¼ 1.00), or day 90 after the procedure (29
[18.1%] vs. 56 [12.6%]; P ¼ .086) nor was there a signiﬁcant
difference in the very elderly ( 75 years vs. < 75 years) on day 30
Table 2 Treatment Characteristics
Parameter Category
Elderly Patients (‡70
years; n [ 160) N (%)
Younger Patients (<70
years; n [ 446) N (%)
P Value
Across
Cohorts
Target Treatment
Approach (%)a
Whole-liver, single-session 45 (28.1) 134 (30.0) .343
Whole-liver, sequential
lobar (<10 wkb)
45 (28.1) 144 (32.3)
Whole-liver, sequential
lobar (10 wkb)
4 (2.5) 26 (5.8)
Right lobe  segmental 49 (30.6) 119 (26.7)
Left lobe  segmental 12 (7.5) 21 (16.8)
Segmental 3 (1.9) 2 (.4)
First Session 90Y Activity
Delivered, GBq; median
(range)
1.09 (0.1-2.0) 1.19 (0.1-2.3) .011
Total 90Y Activity Delivered,
GBq; median (range)
1.24 (0.11-3.13) 1.53 (0.13-5.51) <.001
Number of 90Y-RE
Sessions, N (%)
1 94 (58.8) 207 (46.4) .007
2 58 (36.3) 206 (46.2)
3 6 (3.8) 23 (5.2)
4 2 (1.3) 8 (1.8)
5 0 2 (.4)
Lung Shunt (ﬁrst session),
%, median (range) (%)c
5.2 (0.5-45.0) 4.8 (0.0-31.0) .215
Embolization of Nontarget
Arteries (ﬁrst session);
N (%)d
124 (78.0) 375 (84.1) .089
Hospital Stay Duration <24 h
(ﬁrst session); N (%)e
155 (97.5) 435 (98.0) .752
Total Liver Volume (ﬁrst
session), mL; median
(range)f
1541 (664-3118) 1842 (842-5844) <.001
Treated Liver Volume (ﬁrst
session), mL; median
(range)g
1247 (226-3118) 1486 (246-4772) <.001
Total Tumor Volume (ﬁrst
session), mL; median
(range)h
124 (4.0-1764) 157 (2.8-3329) .268
Tumor-toeTreated Liver Ratio
(ﬁrst session session),
%; median (range)i
15 (0.7-100) 15 (0.1-100) .863
Follow-Up, months;
median (range)
7.9 (0.6-48.6) 8.8 (0.1-77.7) .341
Abbreviation: 90Y-RE ¼ yttrium-90 radioembolization.
aMissing patient baseline data on 1 patient.
bDenotes the interval between ﬁrst and second treatments in patients receiving sequential lobar 90Y-RE.
cMissing patient baseline data on 10 patients.
dMissing patient baseline data on 1 patient.
eMissing patient baseline data on 3 patients.
fMissing patient baseline data on 206 patients.
gMissing patient baseline data on 281 patients.
hMissing patient baseline data on 274 patients.
iMissing patient baseline data on 48 patients.
Andrew S. Kennedy et al(3 [3.1%] vs. 9 [1.8%]; P ¼ .422), day 60 (8 [8.2%] vs. 29 [5.7%];
P ¼ .357), or day 90 (18 [18.4%] vs. 67 [13.2%]; P ¼ .203).
Survival
Kaplan-Meier analyses found that survival differed little between
elderly and younger patients ( 70 years vs. < 70 years: 9.3
months; [95% conﬁdence interval {CI}, 8.0-12.1] vs. 9.7 months
[95% CI, 9.0-11.4]; P ¼ .335) and very elderly patients ( 75 yearsvs. < 75 years: 9.3 months [95% CI, 7.4-12.1] vs. 9.6 months
[95% CI, 9.0-11.2]; P ¼ .987) (Table 4; Figure 1; also see
Supplemental Table 4 in the online version). For the very small
group of patients (n ¼ 35) who had received no previous chemo-
therapy, median survival differed signiﬁcantly in patients  70 years
(11.9 months) versus patients < 70 years (25.2 months). Further
analysis revealed a multitude of reasons for recommending 90Y-RE
as a ﬁrst-line therapy in this elderly cohort (including signiﬁcantClinical Colorectal Cancer June 2016 - 145
Table 3 Common (‡ 1%)a All-Cause Adverse Events by Severity (CTCAE V3) and Any Procedure-Related Event Within Days 0-90 From First 90Y-RE Procedure
System Organ,
Class Elderly Patients (‡70 years; n [ 160) N (%) Younger Patients (<70 years; n [ 446) N (%)
P Value for All
Gradesb
P Value for
Grade ‡3c
CTCAE Grade Unknown Grade 1-2 Grade 3 Unknown Grade 1-2 Grade 3
All (%) 0 77 (48.1) 27 (16.9) 4 217 (48.6) 84 (18.8) .433 .482
Gastrointestinal (%) 0 57 (35.6) 10 (6.3) 3 191 (42.8) 43 (9.6) .017 .152
Abdominal pain (%) 0 37 (23.2) 5 (3.1) 1 (0.2) 156 (35.0) 27 (6.1) <.001 .157
Nausea (%) 1 (0.6) 31 (19.4) 1 (0.6) 3 (0.7) 122 (27.4) 6 (1.3) .038 .736
Vomiting (%) 0 8 (5.0) 2 (1.3) 0 46 (10.3) 6 (1.3) .067 1.000
GI Ulcer (%) 0 0 1 (0.6) 0 7 (1.6) 6 (1.3) .128 .682
Abdominal Distention (%) 0 2 (1.3) 0 0 12 (2.7) 2 (0.4) .260 1.000
Dyspepsia (%) 0 2 (1.3) 0 0 14 (3.1) 0 .260 NA
Gastritis (%) 0 1 (0.6) 1 (0.6) 0 2 (0.4) 1 (0.2) .611 .459
Duodenitis (%) 0 0 1 (0.6) 0 0 0 .264 .264
Intestinal obstruction (%) 0 0 1 (0.6) 0 1 (0.2) 3 (0.7) 1.000 1.000
Constipation (%) 1 (0.6) 5 (3.1) 0 1 (0.2) 13 (2.9) 0 .797 NA
Diarrhea (%) 0 2 (1.3) 0 0 7 (1.6) 0 1.000 NA
Flatulence (%) 0 1 (0.6) 0 0 5 (1.1) 0 1.000 NA
Constitutional (%) 1 67 (41.4) 10 (6.3) 5 167 (37.4) 23 (5.2) .308 .851
Fatigue (%) 0 66 (41.3) 9 (5.6) 3 (0.7) 154 (34.5) 20 (4.5) .135 .838
Fever (%) 1 (0.6) 7 (4.4) 0 1 (0.2) 34 (7.6) 2 (0.4) .219 1.000
Weight loss (%) 0 2 (1.3) 0 1 (0.2) 5 (1.1) 0 1.000 1.000
Peripheral edema (%) 0 0 0 1 (0.2) 1 (0.2) 2 (0.4) .578 .570
Psychiatric (%) 0 11 (6.9) 1 (0.6) 3 (0.7) 29 (6.5) 4 (0.9) 1.000 .688
Anorexia nervosa (%) 0 11 (6.9) 1 (0.6) 3 (0.7) 28 (6.3) 4 (0.9) 1.000 .688
Hepatobiliary (%) 0 11 (6.9) 7 (4.4) 0 35 (7.8) 28 (6.3) .417 .435
Hyperbilirubinemia (%) 0 8 (5.0) 6 (3.8) 0 29 (6.5) 12 (2.7) 1.000 .587
Ascites (%) 0 2 (1.3) 2 (1.3) 1 (0.2) 7 (1.6) 9 (2.0) .615 .741
REILD (%) 0 2 (1.3) 2 (1.3) 5 (1.1) 0 1 (0.2) .302 1.000
Cholecystitis (%) 0 1 (0.6) 0 0 3 (0.7) 1 (0.2) 1.000 1.000
Hepatic failure (%) 0 1 (0.6) 0 0 1 (0.2) 2 (0.4) 1.000 1.000
Musculoskeletal (%) 0 2 (1.3) 0 1 (0.2) 13 (2.9) 1 (0.2) .263 1.000
Back pain (%) 0 1 (0.6) 0 0 4 (0.9) 0 1.000 NA
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Andrew S. Kennedy et alcomorbidities and secondary malignancies), which may have
accounted for these survival differences.
Discussion
MORE is the largest study of RE of any tumor type, including
mCRC, with > 600 patients who were treated between 2002 and
2011. Nevertheless, as with so many studies in the real-world setting
as well as clinical trials with chemotherapy,27,28 there tends to be an
underrepresentation of elderly patients (median age 59 years at
diagnosis in the MORE study) compared with those who are
diagnosed with CRC each year who have a median age of 69 years
(based on the Surveillance, Epidemiology and End Results [SEER]
data 2006-2010)1 (Figure 2). This probably reﬂects the lower
referral rate of elderly patients for liver-directed therapy or the lower
propensity of elderly patients to travel to specialized clinics because
of factors such as frailty and declining cognitive function and
malnutrition,2,16,17 rather than the exclusion of elderly patients
during the pretreatment workup for 90Y-RE. It is notable that
greater proportions of elderly patients than of younger patients
(18.4% vs. 3.3%) were referred for liver-directed therapy and
received 90Y-RE having been considered ineligible for palliative
chemotherapy.
It is of interest that the only other report related speciﬁcally to the
age of patients with mCRC at the time of 90Y-RE21 details results very
similar to those of the MORE study (Table 5). Period of treatment,
eligibility criteria, toxicity assessment with CTCAE, version 3.0, im-
aging interval, and median radioactivity or 90Y delivered are the same in
this study and the Tohme et al study.21 Neither study detected a sta-
tistical difference in any category regarding toxicity, response, and
survival between patients aged < 70 years and patients > 70 years.
Even though the baseline tumor characteristics and liver function
were similar in patients eligible for 90Y-RE, a higher proportion of
very elderly patients (> 75 years) compared with younger (< 75
years) patients had a reduced performance status (ECOG 1-2:
42.2% vs. 32.3%; P ¼ .068). This ﬁnding may have been an un-
derestimate of the actual performance status across the whole cohort
because unfortunately performance status was not routinely assessed
during clinical workup in nearly half of patients. Overall, elderly
patients compared with younger patients were less likely to receive
more than 1 90Y-RE procedure, and a lower volume of liver was
treated with a lower median activity of 90Y-RE. These data suggest
that a more conservative treatment approach was adopted in the
elderly, albeit without a signiﬁcant detrimental effect on survival.
It is encouraging to note that a recently published review of
cancer registry/Medicare data (over a similar period between 2000
and 2009) found that survival in advanced CRC is improving by
4% each year in the elderly after controlling for treatment and tu-
mor location.9 Notably, the registry found that modern chemo-
therapeutic agents (ie, oxaliplatin, irinotecan, and bevacizumab) are
increasingly being adopted for the elderly, perhaps suggesting a shift
in practice patterns9; although our study and other published ana-
lyses suggest that elderly patients were still signiﬁcantly less likely to
receive these agents than were younger patients.4,19,29 Perhaps as a
consequence, a signiﬁcantly greater incidence of grade 1þ neu-
tropenia was observed at baseline in younger patients than in elderly
patients,18,30 even in the relatively small number of patients eval-
uated for neutropenia in this study.Clinical Colorectal Cancer June 2016 - 147
Ta
bl
e
4
Ka
pl
an
-M
ei
er
An
al
ys
is
of
Su
rv
iv
al
in
Al
lP
at
ie
nt
s
an
d
by
Pr
ev
io
us
Li
ne
s
of
Ch
em
ot
he
ra
py
Ch
ar
ac
te
ris
tic
Ca
te
go
ry
Su
rv
iv
al
,m
on
th
sa
El
de
rly
Pa
tie
nt
s
(‡
70
ye
ar
s;
n
[
16
0)
Su
rv
iv
al
,m
on
th
sa
Yo
un
ge
r
Pa
tie
nt
s
(<
70
ye
ar
s;
n
[
44
6)
P
Va
lu
e
Ac
ro
ss
Co
ho
rt
s
N
M
ed
ia
n
95
%
CI
P
Va
lu
eb
N
M
ed
ia
n
95
%
CI
P
Va
lu
eb
Al
l
16
0
9.
3
8.
0-
12
.1
NA
44
6
9.
7
9.
0-
11
.4
NA
.3
35
Pr
ev
io
us
Li
ne
s
of
Ch
em
ot
he
ra
py
90
Y-
RE
ﬁ
rs
t
lin
e
21
12
.8
6.
0-
15
.7
.1
46
14
25
.4
7.
1-
36
.5
<
.0
01
.0
32
90
Y-
RE
se
co
nd
lin
e
50
11
.6
8.
5-
15
.1
15
6
13
.2
10
.5
-1
6.
3
.6
52
90
Y-
RE
th
ird
lin
e
46
9.
1
6.
8-
12
.1
13
8
9.
0
7.
8-
11
.3
.1
67
90
Y-
RE
fo
ur
th
lin
e
pl
us
37
6.
5
3.
8-
9.
3
12
1
8.
3
6.
4-
9.
5
.7
61
Ab
br
ev
ia
tio
ns
:
CI
¼
co
nﬁ
de
nc
e
in
te
rv
al
;
NA
¼
no
t
ap
pl
ic
ab
le
;
90
Y-
RE
¼
yt
rri
um
-9
0
ra
di
oe
m
bo
liz
at
io
n.
a M
ed
ia
n
su
rv
iva
lc
al
cu
la
te
d
by
Ka
pl
an
-M
ei
er
an
al
ys
is
.
b P
va
lu
e
fo
r
w
ith
in
-c
oh
or
t
co
m
pa
ris
on
by
pr
ev
io
us
lin
es
of
ch
em
ot
he
ra
py
.
Figure 1 Kaplan-Meier Survival Curves of Patients With
Metastatic Colorectal Cancer (mCRC) After Treatment
With Ytrrium-90 Radioembolization (90Y-RE)
Stratiﬁed by Age
Safety and Efﬁcacy of Radioembolization in mCRC
148 - Clinical Colorectal Cancer June 2016Overall, we found that 90Y-RE was equally well tolerated in
eligible elderly ( 70 years) and very elderly ( 75 years) and
younger patients, without evidence of an increased risk of REILD or
hepatic dysfunction in the elderly who were assessed up to 90 days
after the procedure. The incidence of grade 3þ events after 90Y-RE
was low. Mild to moderate fatigue was slightly more prominent in
the elderly than in the younger patients, although between-group
differences were not statistically signiﬁcant.
The period between diagnosis and 90Y-RE was longer in the
elderly (P ¼ .011). Despite this, a greater proportion of very elderly
and elderly patients than of younger patients received 90Y-RE asFigure 2 Percentage of Cases by Age at Diagnosis in the
Metastatic Colorectal Cancer Liver Metastases
Outcomes After Radioembolization (MORE) Study and
the Surveillance, Epidemiology and End Results
(SEER) (2006-2010) Database (Vertical Line Shows
the Median Age at Diagnosis in Each Cohort)
Table 5 Comparison of Current Study Parameters With Study
by Tohme
Tohme et al21 Current Study
No. of Patients 107 606
Age, years (no.
patients)
<70 63 446
>70 44 160
(98 patients
>75 years)
Time of Study 2002-2012 2002-2011
90Y Activity Calculation Modiﬁed partition
method
Body surface
area method
Eligibility REBOC REBOC
Treatment Approach Lobar 43% whole liver
43% lobar
Posttreatment Overnight stay
in hospital
99% discharged
same day
Toxicity CTCAE, version 3.0; d
1-90 after procedure
CTCAE, version 3.0;
d 1 until death
Imaging
Assessment
RECIST 1.1 up to
6 mo after 90Y-RE
RECIST 1.0 and 1.1
at 3 mo after 90Y-RE
Survival From d of 90Y-RE
procedure
From d of
90Y-RE procedure
Abbreviations: CTCAE ¼ Common Terminology Criteria for Adverse Events; REBOC ¼ Radio-
embolization Brachytherapy Oncology Consortium; 90Y-RE ¼ ytrrium-90 radioembolization.
Andrew S. Kennedy et alﬁrst-line treatment (18.4% and 13.6% vs. 3.3%, respectively), with
fewer elderly patients receiving the procedure as second- or
third-line therapy (57.1%, 62.4% vs. 68.6%, respectively). Radio-
embolization was considered in preference to systemic chemo-
therapy in up to a ﬁfth of very elderly patients with mCRC, many of
whom had refused further chemotherapy at the end of adjuvant
treatment after resection of the primary tumor or had signiﬁcant
comorbidities and secondary malignancies. For this reason, median
survival with ﬁrst-line 90Y-RE was lower in the elderly than in
younger patients (12.8 months vs. 25.4 months), which is consis-
tent with recent experience with capecitabine and oxaliplatin in
elderly and frail patients (median survival, 11 months)31 and in the
UK MRC open-label FOCUS2 study of elderly patients  70 years
(median age, 75 years; median survival, 10.2-12.4 months).7 In the
chemotherapy-refractory setting, however, overall survival was not
statistically different in elderly and younger patients when RE was
given either as second-line treatment (11.6 vs. 13.2 months) or
third-line treatment (9.1 vs. 9.0 months).
Comparisons of the MORE study with prospective randomized
controlled trials are hampered by differences in the selection
criteria between these studies. For example, most randomized
controlled trials in the elderly tend to select patients with a good
performance status (ie, either an ECOG score of 0 or a KPS score
of 80%-100%) and many only in the ﬁrst-line setting.5,32-35 For
example, 69%-88% of elderly patients in studies using cetuximab
had a good performance status36,37 compared with only 58% of
patients in the MORE study. Nevertheless, our experience with
RE in the second-line setting and beyond in elderly patientscompares favorably with the survival beyond progression of 10 to
12 months in the Bevacizumab Regimens: Investigation of
Treatment Effects and Safety (BRiTE) study of bevacizumab-
based ﬁrst-line therapy,33 but without the increased risk of sig-
niﬁcant toxicity associated with systemic chemotherapy in the
elderly, who frequently require dose reductions.5,18,38-42 With the
risk of toxicities to chemotherapy ampliﬁed in frail patients16 as
well as beyond ﬁrst-line therapy,18 RE appears to be a particularly
attractive alternative for the management of elderly patients with
liver-dominant mCRC. The 90-day all cause mortality seen in this
study is in keeping with that expected in patients who have pro-
gressed beyond fourth-line chemotherapy or who have been
medically unable to receive multiagent chemotherapy beyond ﬁrst-
line regimens. The treatment intensity (activity delivered) was not
signiﬁcantly different between young and elderly patient cohorts.
The percentage of patients receiving whole liver versus lobar
treatments was also the same in each group. Very few (< 10)
patients were reported to have received any additional systemic
therapy beyond RE, which is not unusual given that they had
already received multiple lines of therapy before RE.
Conclusion
For patients with unresectable liver-dominant mCRC who meet
the eligibility criteria for RE, 90Y-RE appears to be as effective and
as well tolerated in elderly patients as in younger candidates.
Because elderly patients receive less intense systemic therapy, liver
tumor control may provide signiﬁcant beneﬁts in select patients.
Clinical Practice Points
 Patients with mCRC who are older than 65 years constitute at
least 60% of new cases yearly, and 36% of these patients are 75
years or older. However, for a variety of reasons, patients > 70
years (“elderly”) do not receive anticancer therapy that is as
intensive as that given to younger patients with mCRC.
 Elderly patients are often ineligible for clinical studies in mCRC,
and as such there is a knowledge gap in how to optimally care for
them.
 The current question addressed in this report is the safety and
efﬁcacy of liver-directed radiation 90Y-RE delivered intraarterially
and permanently implanted into liver metastases in elderly
patients.
 Only 1 other report appears in the current literature con-
cerning elderly patients receiving this therapy, and it has a
modest number of participants. It describes treatment eligi-
bility and approach to delivery of radiation similar to the
current report.
 However, the current study greatly expands the level of detailed
information on treatment and outcome, and includes 4 times as
many patients as the previous report. In addition, there are new
data provided for 95 patients who were older than 75 years when
treated.
 Overall, the complimentary and new data reported will enable
conﬁdence in offering liver irradiation to patients older than 70
years. These patients are underserved currently, and thus this
approach is likely to directly beneﬁt both the quality and
quantity of life in elderly patients.Clinical Colorectal Cancer June 2016 - 149
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Supplemental Table 1 Baseline Patient and Disease Characteristics and Previous Procedures in the Very Elderly Compared With
Younger Patients
Parameter Category
Very Elderly Patients (‡75
years; n [ 98) N (%)a
Younger Patients (<75
years; n [ 508) N (%)a
P Value
Across
Cohorts
Sex, N (%) Female/male 33 (33.7)/65 (66.3) 200 (39.4)/308 (60.6) .309
Age, years Mean  SD 80.2  3.8 57.9  10.4 <.001
(range) (75.0-91.9) (20.8-74.9)
Race, N (%)b White or Caucasian 59 (79.7) 339 (77.4) .213c
Black or African American 8 (10.8) 59 (13.5)
Hispanic or Latino 2 (2.7) 15 (3.4)
Asian 2 (2.7) 10 (2.3)
Other 3 (4.1) 15 (3.4)
Unknown 24 70
ECOG Performance Status,
N (%)d
0 25 (54.3) 143 (67.8) .068e
1 16 (34.8) 56 (26.5)
2 4 (8.7) 10 (4.7)
3 1 (2.2) 2 (0.9)
Unknown 52 297
Site of Primary Tumor,
N (%)f
Colon 82 (84.5) 361 (71.2) .189g
Rectum 2 (2.1) 26 (5.1)
Colorectal 13 (13.4) 120 (23.7)
Primary Tumor in Situ
N (%)h
5 (5.3) 73 (14.5) .012
Metastases, N (%)i,j Metachronous 43 (48.3) 130 (27.1) <.001
Synchronous 46 (51.7) 350 (72.9)
Extrahepatic Metastases,
N (%)
31 (31.6) 182 (35.8) 0.488
Ascites, N (%)k Yes 4 (4.2) 24 (4.8) .792
Previous Liver-Directed
Procedures, N (%)
Surgery and/or ablation 27 (27.6) 141 (27.8) 1.000
Vascular/percutaneous 4 (4.1) 33 (6.5) .491
Upper abdominal radiation 1 (1.0) 6 (1.2) 1.000
Previous Lines of Systemic
Chemotherapy for mCRC,
N (%)
RE ﬁrst line 18 (18.9) 17 (3.5) <.005
RE second line 30 (31.6) 176 (36.1) .004l
RE third line 26 (27.4) 158 (32.4)
RE fourth line þ 21 (22.1) 137 (28.0)
Unknown 3 20
Previous Chemotherapy
Agents, N (%)
Fluoropyrimidine 81(82.7) 454 (89.4) .084
Oxaliplatin 60 (61.2) 397 (78.1) <.001
Irinotecan 33 (33.7) 263 (51.8) .001
Bevacizumab 51(52.0) 358 (70.5) <.001
EGFR inhibitor 22 (22.4) 144 (28.3) .266
Time From mCRC
Identiﬁcation to RE, mom
Median (range) 17.0 (0.4-78.0) 16.1 (0.6-96.3) .042
Tumor-to-Target, N (%) <25 62 (71.3) 326 (69.2) .589
Liver (ﬁrst session), N (%)n 25-50 22 (25.3) 126 (26.8)
>50 3 (3.4) 19 (4.0)
Albumin, g/dLk Median (IQR) 3.6 (0.7) 3.7 (0.8) .472
CTCAE grade 1, N (%) 36 (37.9) 163 (32.9) .345
Total Bilirubin, mg/dLo Median (IQR) 0.7 (0.4) 0.6 (0.4) .908
Safety and Efﬁcacy of Radioembolization in mCRC
151.e1 - Clinical Colorectal Cancer June 2016
Supplemental Table 1 Continued
Parameter Category
Very Elderly Patients (‡75
years; n [ 98) N (%)a
Younger Patients (<75
years; n [ 508) N (%)a
P Value
Across
Cohorts
CTCAE grade 1, N (%) 3 (3.2) 34 (6.8) .246
Alkaline phosphatase, U/Lp Median (IQR) 148.5 (127.0) 145.0 (144.0) .204
CTCAE grade 1, N (%) 55 (58.5) 296 (59.4) .909
Creatinine, mg/dLq Median (IQR) 1.0 (0.3) 0.8 (0.3) <.001
CTCAE grade 1, N (%) 10 (10.4) 16 (3.2) .004
Hemoglobin, g/dLr Median (IQR) 12.2 (2.2) 12.5 (2.6) .600
CTCAE grade 1, N (%) 44 (45.4) 194 (39.0) .259
Neutrophils,109/Ls Median (IQR) 4.4 (2.1) 4.1 (2.2) .404
CTCAE grade 1, N (%) 1 (7.7) 7 (6.1) .589
Abbreviations: CTCAE ¼ Common Terminology Criteria for Adverse Events; ECOG ¼ Eastern Cooperative Oncology Group; EGFR ¼ endothelial growth factor receptor; IQR ¼ interquartile range;
mCRC ¼ metastatic colorectal carcinoma; RE ¼ radioembolization; SD ¼ standard deviation.
aCalculated as a proportion of patients with known baseline data.
bMissing patient baseline data on 94 patients.
cP value: comparison of Caucasian versus other.
dMissing patient baseline data on 349 patients.
eP value: comparison of ECOG performance status 0-1 versus 2þ.
fMissing patient baseline data on 2 patients.
gP value: comparison of colon versus rectum.
hMissing patient baseline data on 6 patients.
iMissing patient baseline data on 37 patients.
jSynchronous deﬁned as the identiﬁcation of metastases within 4 months (120 days) of ﬁnding the primary tumor.
kMissing patient baseline data on 15 patients.
lP value: continuous variable across all lines of chemotherapy.
mMissing patient baseline data on 29 patients.
nMissing patient baseline data on 48 patients.
oMissing patient baseline data on 13 patients.
pMissing patient baseline data on 14 patients.
qMissing patient baseline data on 11 patients.
rMissing patient baseline data on 12 patients.
sMissing patient baseline data on 479 patients.
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Supplemental Table 2 Treatment Characteristics in Very Elderly Compared With Younger Patients
Parameter Category
Very Elderly Patients (‡75
years; n [ 98) N (%)
Younger Patients (<75
years; n [ 508) N (%)
P Value Across
Cohorts
Target Treatment
Approach, N (%)
Whole liver, single session 22 (22.4) 109 (21.5) .343
Whole liver, sequential lobar
(<10 wka)
27 (27.6) 190 (37.4)
Whole liver, sequential lobar
(10 wka)
8 (8.2) 47 (9.2)
Right lobe  segmental 31 (31.6) 134 (26.4)
Left lobe  segmental 8 (8.2) 25 (4.9)
Segmental 2 (2.0) 3 (0.6)
First Session 90Y Activity
Delivered, GBq; median
(range)
1.02 (0.11-2.04) 1.19 (0.13-2.29) .011
Total 90Y Activity Delivered,
GBq; median (range)
1.22 (0.11-3.12) 1.49 (0.13-5.51) <.001
No. of 90Y-RE sessions,
N (%)
1 61 (62.2) 240 (47.2) .007
2 33 (33.7) 231 (45.5)
3 4 (4.1) 25 (4.9)
4 0 10 (2.0)
5 0 2 (0.4)
Lung Shunt (ﬁrst session),
%, median (range)b
5.0 (0.5-45.0) 4.8 (0.0-31.0) .290
Embolization of Nontarget
Arteries (ﬁrst session),
N (%)c
70 (72.2) 429 (84.4) .005
Hospital stay duration
<24 h (ﬁrst session), N (%)d
94 (96.9) 496 (98.0) .449
Total Liver Volume (ﬁrst
session), mL, median
(range)e
1481 (664-2635) 1825 (842-5844) <.001
Treated Liver Volume (ﬁrst
session), mL, median
(range)f
1179 (226-2083) 1451 (246-4772) <.001
Total Tumor Volume (ﬁrst
session), mL, median
(range)g
76.4 (4.0-1080) 164 (2.8-3329) .039
Tumor-toeTreated Liver
Ratio (ﬁrst session),
%, median (range)h
10 (0.9-71) 15 (0.1-100) .589
Follow-Up, mo, median
(range)
7.4 (0.6-48.6) 8.9 (0.1-77.7) .597
P value for continuous variables by 1-way analysis of variance, P values for dichotomous variables by the Fisher exact test, nominal categorical variables by c2 general association test, and P value for
ordinal variables by Wilcoxon rank sum test.
Abbreviation: 90Y ¼ yttrium 90; RE ¼ radioembolization.
aDenotes the interval between ﬁrst and second treatments in patients receiving sequential lobar 90Y-RE.
bMissing patient baseline data on 10 patients.
cMissing patient baseline data on 1 patient.
dMissing patient baseline data on 3 patients.
eMissing patient baseline data on 206 patients.
fMissing patient baseline data on 281 patients.
gMissing patient baseline data on 274 patients.
hMissing patient baseline data on 48 patients.
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Supplemental Table 3 Common (‡ 1%)a All-Causality Adverse Events by Severity (CTCAE, version 3) and Any Procedure-Related Event Within Days 0-90 from First 90Y-RE Procedure
System Organ, Class Very Elderly Patients (‡75 years; n [ 98) N (%) Younger Patients (<75 years; n [ 508) N (%)
P Value for
All Gradesb
P Value for
Grade ‡3c
CTCAE Grade Unknown Grade 1-2 Grade 3 Unknown Grade 1-2 Grade 3
All, N (%) 0 45 (45.9) 15 (15.3) 4 (0.8) 249 (49.0) 96 (18.9) .158 .398
Gastrointestinal, N (%) 0 35 (35.7) 4 (4.1) 3 (0.6) 213 (41.9) 49 (9.6) .027 .057
Abdominal pain, N (%) 0 23 (23.5) 1 (1.0) 1 (0.2) 170 (33.5) 31 (6.1) .004 .029
Nausea, N (%) 1 (1.0) 20 (20.4) 0 3 (0.6) 133 (26.2) 7 (1.4) .214 1.000
Vomiting, N (%) 0 5 (5.1) 1 (1.0) 0 49 (9.6) 7 (1.4) .201 1.000
Ulcer, N (%) 0 0 0 0 7 (1.4) 7 (1.4) .142 .605
Abdominal distention, N (%) 0 1 (1.0) 0 0 13 (2.6) 2 (0.4) .490 1.000
Dyspepsia, N (%) 0 0 0 0 16 (3.2) 0 .088 NA
Gastritis, N (%) 0 1 (1.0) 1 (1.0) 0 2 (0.4) 1 (0.2) .186 .298
Duodenitis, N (%) 0 0 1 (1.0) 0 0 0 .162 .162
Intestinal obstruction, N (%) 0 0 1 (1.0) 0 1 (0.2) 3 (0.6) .587 .507
Constipation, N (%) 1 (1.0) 4 (4.0) 0 1 (0.2) 14 (2.8) 0 .348 .298
Diarrhea, N (%) 0 2 (2.0) 0 0 7 (1.4) 0 .644 NA
Flatulence, N (%) 0 0 0 0 6 (1.2) 0 .596 NA
Constitutional 1 (1.0) 39 (39.8) 4 (4.1) 5 (1.0) 195 (38.4) 29 (5.7) 1.000 .659
Fatigue, N (%) 0 39 (39.8) 4 (4.1) 3 (0.6) 181 (35.6) 25 (4.9) .655 .805
Fever, N (%) 1 (1.0) 5 (5.1) 0 1 (0.2) 36 (7.1) 2 (0.4) .680 .507
Weight loss, N (%) 0 2 (2.0) 0 1 (0.2) 5 (1.0) 0 .622 1.000
Peripheral edema, N (%) 0 0 0 1 (0.2) 1 (0.2) 2 (0.4) 1.000 1.000
Psychiatric 0 7 (7.1) 0 3 (0.6) 33 (6.5) 5 (1.0) 1.000 .366
Anorexia nervosa, N (%) 0 7 (7.1) 0 0 32 (6.3) 5 (1.0) 1.000 .366
Hepatobiliary, N (%) 0 6 (6.1) 3 (3.1) 0 40 (7.9) 32 (6.3) .255 .341
Hyperbilirubinemia, N (%) 0 4 (4.0) 2 (2.0) 0 33 (6.5) 16 (3.1) .338 .751
Ascites, N (%) 0 0 1 (1.0) 1 (0.2) 9 (1.8) 10 (2.0) .226 .701
REILD, N (%) 0 2 (2.0) 1 (1.0) 5 (1.0) 0 2 (0.4) .210 1.000
Cholecystitis, N (%) 0 1 (1.0) 0 0 3 (0.6) 1 (0.2) .587 1.000
Hepatic failure, N (%) 0 0 0 0 2 (0.4) 2 (0.4) 1.000 1.000
Musculoskeletal, N (%) 0 2 (2.0) 0 1 (0.2) 13 (2.6) 1 (0.2) 1.000 1.000
Back pain, N (%) 0 1 (1.0) 0 0 4 (0.8) 0 .587 NA
Cardiac disorders, N (%) 0 0 2 (2.0) 0 1 (0.2) 0 .070 .026
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Supplemental Table 4 Kaplan-Meier Analysis of Survival in All Patients and by Previous Lines of Chemotherapy
Characteristic Category
Survival, monthsa Very Elderly Patients (‡75 years; n [ 98) Survival, monthsa Younger Patients (<75 years; n [ 508)
P Value Across
CohortscN Median (95% CI) P Valueb N Median (95% CI) P Valueb
All 98 9.3 (7.4-12.1) NA 508 9.6 (9.0-11.2) NA .987
Previous Lines of
Chemotherapy
RE ﬁrst line 18 11.9 (4.0-15.6) .316 17 25.2 (9.3-36.5) <.001 .041
RE second line 30 12.1 (7.4-20.2) 176 13.0 (10.5-14.6) .733
RE third line 26 8.7 (5.0-12.1) 158 9.0 (7.8-10.4) .360
RE fourth line þ 21 6.6 (4.4-9.3) 137 8.2 (6.4-9.4) .963
Abbreviations: CI ¼ conﬁdence interval; NA ¼ not applicable; RE ¼ radioembolization.
aMedian survival calculated by Kaplan-Meier analysis.
bP value for within-cohort comparison by previous lines of chemotherapy.
cP value for across-cohort comparison.
Supplemental Table 3 Continued
System Organ, Class Very Elderly Patients (‡75 years; n [ 98) N (%) Younger Patients (<75 years; n [ 508) N (%)
P Value for
All Gradesb
P Value for
Grade ‡3c
Vascular Disorders, N (%) 0 2 (2.0) 2 (2.0) 1 (0.2) 5 (1.0) 4 (0.8) .259 .316
Respiratory, N (%) 1 (1.0) 1 (1.0) 1 (1.0) 1 (0.2) 16 (3.1) 1 (0.2) 1.000 .125
Inﬂuenza, N (%) 0 0 0 1 (0.2) 10 (2.0) 0 .227 1.000
This table reports the highest grade of adverse event reported by each patient within each time interval.
Abbreviations: NA ¼ not applicable; REILD ¼ radioembolization-induced liver disease.
aAt all time points.
bP value across all grades.
cP value for grades  3.
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Supplemental Figure 1 Kaplan-Meier Survival Curves of
Patients With Metastatic Colorectal
Cancer (mCRC) After
Radioembolization (RE) Using Yttrium-
90 (90Y) Resin Microspheres, Stratiﬁed
by Age (< 75 years vs. ‡ 75 years)
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